Arbutus Announces Late-Breaker Abstract Accepted For Presentation At AASLD – The Liver Meeting 2021
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms